Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting
University of Zurich
600 participants
Mar 1, 2022
OBSERVATIONAL
Conditions
Summary
This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.
Eligibility
Inclusion Criteria3
- Participant in the SHCS
- All SHCS participants initiating the CAB+RPV LA regimen
- All SHCS participants on SOC oral regimen
Exclusion Criteria1
- Not participating in the SHCS
Interventions
CAB 30 mg Film-coated tablets
RPV 25 mg film-coated tablets
CAB LA 600 mg prolonged release suspension for injection (3 mL)
RPV LA 900 mg prolonged release suspension for injection (3 mL)
HIV-1 latent reservoir size
Proviral DNA
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06405464